dihydroxyphenylalanine has been researched along with Autosomal Dominant Striatonigral Degeneration in 2 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed [18F]6-fluoro-L-dopa (6-FD) and [11C]raclopride (RAC) PET studies in six patients with Machado-Joseph disease (MJD) (age, 17 to 61 years; duration of illness, 3 to 10 years), normal controls (n = 10 in 6-FD-PET, n = 8 in RAC-PET), and patients with idiopathic parkinsonism (n = 15 in 6-FD-PET)." | 7.69 | Fluorodopa and raclopride PET analysis of patients with Machado-Joseph disease. ( Calne, DB; Hashimoto, S; MacLeod, P; Rouleau, GA; Schulzer, M; Shinotoh, H; Silveira, I; Snow, BJ; Thiessen, B, 1997) |
| "We performed [18F]6-fluoro-L-dopa (6-FD) and [11C]raclopride (RAC) PET studies in six patients with Machado-Joseph disease (MJD) (age, 17 to 61 years; duration of illness, 3 to 10 years), normal controls (n = 10 in 6-FD-PET, n = 8 in RAC-PET), and patients with idiopathic parkinsonism (n = 15 in 6-FD-PET)." | 3.69 | Fluorodopa and raclopride PET analysis of patients with Machado-Joseph disease. ( Calne, DB; Hashimoto, S; MacLeod, P; Rouleau, GA; Schulzer, M; Shinotoh, H; Silveira, I; Snow, BJ; Thiessen, B, 1997) |
| "The subtype IV of Machado-Joseph disease (MJD), characterized by parkinsonism variably combined with ataxia, distal atrophy, and sensory loss, has been all but ignored in recent reports of MJD, including those describing the molecular biologic substrate of the disease." | 1.29 | Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. ( Lang, AE; Rogaeva, EA; St George-Hyslop, PH; Tuite, PJ, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tuite, PJ | 1 |
| Rogaeva, EA | 1 |
| St George-Hyslop, PH | 1 |
| Lang, AE | 1 |
| Shinotoh, H | 1 |
| Thiessen, B | 1 |
| Snow, BJ | 1 |
| Hashimoto, S | 1 |
| MacLeod, P | 1 |
| Silveira, I | 1 |
| Rouleau, GA | 1 |
| Schulzer, M | 1 |
| Calne, DB | 1 |
2 other studies available for dihydroxyphenylalanine and Autosomal Dominant Striatonigral Degeneration
| Article | Year |
|---|---|
Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion.
Topics: Chromosomes, Human, Pair 14; Dihydroxyphenylalanine; DNA; Female; Humans; Machado-Joseph Disease; Ma | 1995 |
Fluorodopa and raclopride PET analysis of patients with Machado-Joseph disease.
Topics: Adolescent; Adult; Caudate Nucleus; Cerebellum; Dihydroxyphenylalanine; Dopamine Antagonists; Female | 1997 |